AngioDynamics and PERT Consortium Launch $750K Pulmonary Embolism Research Fund
Event summary
- AngioDynamics and The PERT Consortium® launched the ALPHA-PE Research Fund on February 5, 2026, to support investigator-led pulmonary embolism (PE) research.
- The fund will award grants ranging from $50,000 to $750,000 over one to three years to address critical evidence gaps in PE care.
- Pulmonary embolism affects approximately one in 1,000 people annually and contributes to more than 50,000 deaths each year in the United States.
- The initiative aims to accelerate clinically relevant evidence to inform care delivery and advance understanding of PE management.
The big picture
The launch of the ALPHA-PE Research Fund underscores the growing emphasis on independent, physician-led research to address critical evidence gaps in pulmonary embolism care. This initiative aligns with broader industry trends toward data-driven healthcare solutions and collaborative efforts to improve patient outcomes. The fund's scale, with grants up to $750,000, positions it as a significant investment in advancing PE management and treatment options.
What we're watching
- Research Impact
- How the ALPHA-PE Research Fund will affect the pace of clinically relevant evidence generation in pulmonary embolism care.
- Industry Collaboration
- Whether this partnership model can sustain long-term advancements in PE treatment and management.
- Regulatory Influence
- The extent to which independent, physician-led research will shape future regulatory standards for PE care.
Related topics